Abstract
Abstract 3229
Poster Board III-166
Low platelet count prior to mobilization is a significant predictive factor for mobilization failure in patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) undergoing autologous hematopoietic stem cell (HSC) transplantation (auto-HSCT; Hosing C, et al, Am J Hematol. 2009). The purpose of this study is to assess the efficacy of HSC mobilization with plerixafor plus G-CSF in patients with concomitant thrombocytopenia undergoing auto-HSCT.
Patients who had failed successful HSC collection with any mobilization regimen were remobilized with plerixafor plus G-CSF as part of a compassionate use program (CUP). Mobilization failure was defined as the inability to collect 2 ×106 CD34+ cells/kg or inability to achieve a peripheral blood count of ≥10 CD34+ cells/μl without having undergone apheresis. As part of the CUP, G-CSF (10μg/kg) was administered subcutaneously (SC) every morning for 4 days. Plerixafor (0.24 mg/kg SC) was administered in the evening on Day 4, approximately 11 hours prior to the initiation of apheresis the following day. On Day 5, G-CSF was administered and apheresis was initiated. Plerixafor, G-CSF and apheresis were repeated daily until patients collected the minimum of 2 × 106 CD34+ cells/kg for auto-HSCT. Patients in the CUP with available data on pre-mobilization platelet counts were included in this analysis. While patients with a platelet count <85 × 109/L were excluded from the CUP, some patients received waivers and were included in this analysis. Efficacy of remobilization with plerixafor + G-CSF was evaluated in patients with platelet counts ≤ 100 × 109/L or ≤ 150 × 109/L.
Of the 833 patients in the plerixafor CUP database, pre-mobilization platelet counts were available for 219 patients (NHL=115, MM=66, HD=20 and other=18.). Of these, 92 patients (NHL=49, MM=25, HD=8 and other=10) had pre-mobilization platelet counts ≤ 150 × 109/L; the median platelet count was 115 × 109/L (range, 50-150). The median age was 60 years (range 20-76) and 60.4% of the patients were male. Fifty-nine patients (64.1%) collected ≥2 × 109 CD34+ cells/kg and 13 patients (14.1%) achieved ≥5 × 106 CD34+ cells/kg. The median CD34+ cell yield was 2.56 × 106 CD34+ cells/kg. The proportion of patients proceeding to transplant was 68.5%. The median time to neutrophil and platelet engraftment was 12 days and 22 days, respectively. Similar results were obtained when efficacy of plerixafor + G-CSF was evaluated in 29 patients with platelet counts ≤ 100 × 109/L (NHL=12, MM=10, HD=3 and other=4). The median platelet count in these patients was 83 × 109/L (range, 50-100). The median age was 59 years (range 23-73) and 60.4% of the patients were male. The minimal and optimal cell dose was achieved in 19(65.5%) and 3(10.3%) patients, respectively. The median CD34+ cell yield was 2.92 × 106 CD34+ cells/kg. The proportion of patients proceeding to transplant was 62.1%. The median time to neutrophil and platelet engraftment was 12 days and 23 days, respectively.
For patients mobilized with G-CSF alone or chemotherapy ±G-CSF, a low platelet count prior to mobilization is a significant predictor of mobilization failure. These data demonstrate that in patients with thrombocytopenia who have failed prior mobilization attempts, remobilization with plerixafor plus G-CSF allows ∼65% of the patients to collect the minimal cell dose to proceed to transplantation. Thus, in patients predicted or proven to be poor mobilizers, addition of plerixafor may increase stem cell yields. Future studies should investigate the efficacy of plerixafor + G-CSF in front line mobilization in patients with low platelet counts prior to mobilization.
Efficacy of remobilization with plerixafor + G-CSF in patients with concurrent thrombocytopenia
| . | Platelet Count ≤ 100 × 109/L N=29 . | Platelet Count ≤ 150 × 109/L N=92 . |
|---|---|---|
| No. of patients collecting ≥ 2 × 106 CD34+ cells/kg (%) | 19 (65.5%) | 59 (64.1%) |
| No. of patients collecting ≥ 5 × 106 CD34+ cells/kg (%) | 3 (10.3%) | 13 (14.1%) |
| Median number (range) of CD34+ cells/kg (x 106) collected | 2.92 (0.27-27.5) | 2.56 (0-27.5) |
| No. of patients proceeding to transplant (%) | 18 (62.1%) | 63 (68.5%) |
| Median (Range) days to neutrophil engraftment | 12 (8-28) | 12 (8-28) |
| Median (Range) days to platelet engraftment | 23 (15-42) | 22 (13-66) |
| . | Platelet Count ≤ 100 × 109/L N=29 . | Platelet Count ≤ 150 × 109/L N=92 . |
|---|---|---|
| No. of patients collecting ≥ 2 × 106 CD34+ cells/kg (%) | 19 (65.5%) | 59 (64.1%) |
| No. of patients collecting ≥ 5 × 106 CD34+ cells/kg (%) | 3 (10.3%) | 13 (14.1%) |
| Median number (range) of CD34+ cells/kg (x 106) collected | 2.92 (0.27-27.5) | 2.56 (0-27.5) |
| No. of patients proceeding to transplant (%) | 18 (62.1%) | 63 (68.5%) |
| Median (Range) days to neutrophil engraftment | 12 (8-28) | 12 (8-28) |
| Median (Range) days to platelet engraftment | 23 (15-42) | 22 (13-66) |
Micallef:Genzyme Corporation: Membership on an entity's Board of Directors or advisory committees, Research Funding. Jacobsen:Genzyme Corporation: Research Funding. Shaughnessy:Genzyme Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Marulkar:Genzyme Corporation: Employment, Equity Ownership. Mody:Genzyme Corporation: Employment, Equity Ownership. van Rhee:Genzyme Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.
Author notes
Asterisk with author names denotes non-ASH members.
